TL 2 Million in Support from TÜBİTAK

Under the TÜBİTAK 1003 program, the projects of BAU Faculty of Engineering and Natural Sciences faculty members Assist. Prof. Dr. Berke Gür, Assoc. Prof. Dr. Gülay Bulut and Dr. Yongki Yoon have qualified for support with a total budget of TL 2 million.

NEXT-GENERATION UNDERWATER ROBOTS ARE ON THE WAY

The project titled "Development and Design of an Unmanned Robotic Cuttlefish for Underwater Manipulation," managed and led by Assist. Prof. Dr. Berke Gür, received support from TÜBİTAK. The project aims to develop a next-generation underwater robot that will make underwater intervention possible with a dexterity that existing unmanned underwater vehicles cannot provide. Built with biomimetic design, innovative materials and advanced control methods, these robots will incorporate underwater communication technologies. The project team includes Assist. Prof. Dr. Berke Gür, Prof. Dr. Lütfi Arda and Dr. Yongki Yoon.

AUTONOMOUS TRANSPORT VEHICLES FOR THE FACTORIES OF THE FUTURE

The other project, titled "Development of autonomous transporters and the necessary human-machine and machine-machine interfaces for smart factories" and led by Dr. Yongki Yoon, plans to realize autonomous transport vehicles for use in the factories of the future shaped by Industry 4.0 approaches, along with the human-machine and machine-machine interfaces and communication platforms needed for them to operate integrated with the entire in-factory system. The project team includes Dr. Yongki Yoon, Assist. Prof. Dr. Berke Gür and Prof. Dr. Nafiz Arıca.

CANCER TREATMENT WILL BE PERSONALIZED

The project titled "Development of Drug Candidates Targeting the Oncogenic K-ras Protein Using the Phage Display Method," to be led by Assoc. Prof. Dr. Gülay Bulut, aims to develop drugs against the K-ras protein, one of the most frequently mutated proteins in cancer. The aim is for these drug candidates to also be effective in treating other types of cancer in which K-ras is mutated, and for the scientific data obtained from the study to support personalized treatment for cancer patients in the future.